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Insulin rapidly suppresses hepatic glucose produc-
tion and slowly decreases expression of genes en-
coding gluconeogenic proteins. In this study, we
show that an immediate effect of insulin is to redirect
newly synthesized glucose-6-phosphate to glycogen
without changing the rate of gluconeogenesis. This
process requires hepatic Akt2, as revealed by blunt-
ed insulin-mediated suppression of glycogenolysis
in the perfusedmouse liver, elevated hepatic glucose
production during a euglycemic-hyperinsulinemic
clamp, or diminished glycogen accumulation during
clamp or refeeding in mice without hepatic Akt2.
Surprisingly, the absence of Akt2 disrupted glycogen
metabolism independent of GSK3a and GSK3b
phosphorylation, which is thought to be an essential
step in the pathway by which insulin regulates
glycogen synthesis through Akt. These data show
that (1) the immediate action of insulin to suppress
hepatic glucose production functions via an Akt2-
dependent redirection of glucose-6-phosphate to
glycogen, and (2) insulin increases glucose phos-
phorylation and conversion to glycogen independent
of GSK3.
INTRODUCTION
One of the most important metabolic events that accompany
the intake of nutrients is the suppression of hepatic glucose
output. During fasting, glucose produced by the liver provides
energy to organs, such as brain, that are dependent on carbo-
hydrates. Glucose released from liver derives from de novo
synthesis from substrates like glycerol, lactate, and amino
acids (gluconeogenesis) and the breakdown of stored glycogen
(glycogenolysis). In the postprandial state, these processes are
largely suppressed by the increase in insulin and glucose and
the decrease in glucagon (Lin and Accili, 2011). Understanding
the control of hepatic glucose production is of particular impor-
tance given that the prevalence of obesity, insulin resistance,and type 2 diabetes mellitus (T2DM) has reached epidemic
proportions.
In recent years, most of the research on the hepatic actions of
insulin has focused on the hormone’s transcriptional targets
(Lin and Accili, 2011). Considerable evidence supports a model
in which insulin, through serine/threonine kinase Akt (also
known as protein kinase B) phosphorylation and inhibition of
the forkhead box O (FoxO), reduces the expression of genes
encoding putatively rate-limiting enzymes of gluconeogenesis,
most notably the catalytic subunit of glucose-6-phosphatase
(encoded by the G6pc gene) and phosphoenolpyruvate carbox-
ykinase (PEPCK, encoded by the Pck1 gene) (Lin and Accili,
2011). However, in a recent study, we noted a mild impairment
in the ability of insulin to suppress hepatic glucose output in
the liver-specific Akt2 null mice unaccompanied by any changes
in gene expression (Lu et al., 2012). Understanding the mecha-
nism for this defect is the subject of this article. We found that
the immediate response to insulin is to reduce glycogenolysis
and redirect newly synthesized glucose-6-phosphate to
glycogen, with no apparent effect on the rate of gluconeogen-
esis. Moreover, Akt2 is required for this effect of insulin, but
not via signaling though the canonical GSK3 glycogen synthase
(GS) pathway.
RESULTS
Liver-Specific Akt2Knockout Mice Are Insulin Resistant
but Display Normal Regulation of Gene Expression
Although germline Akt2 knockout (KO) mice display mild glucose
intolerance and elevated hepatic glucose production, liver-
specific deletion of Akt2 does not lead to strikingly abnormal
glycemia under normal or insulin-resistant conditions (Cho
et al., 2001; Lu et al., 2012; Wan et al., 2011). As assessed by
euglycemic-hyperinsulinemic clamp, the glucose infusion rate
(GIR) was lower in Akt2(lox/lox); AFP > CRE mice than Akt2(lox/lox)
mice (henceforth referred to as control mice or controls), sug-
gesting an insulin-resistant state (Figure 1A, left). Basal hepatic
glucose production (HGP) was the same between the two
groups, but suppression of HGP by insulin was significantly
blunted in Akt2(lox/lox); AFP > CREmice (Figure 1A). The mildness
of the defect is due to functional rescue by Akt1, which repre-
sents about 15% of the Akt protein in hepatocytes, the
remainder being Akt2 (Lu et al., 2012). Surprisingly, the rate ofCell Metabolism 18, 99–105, July 2, 2013 ª2013 Elsevier Inc. 99
Figure 1. Deletion of Akt2 in the Liver Re-
sults in Hepatic Insulin Resistance
(A) Chow-fed 2-month-old male control
(Akt2(lox/lox)) and liver-specific Akt2 KO (Akt2(lox/lox);
AFP > CRE) mice were subjected to a euglycemic-
hyperinsulinemic clamp. GIR, glucose infusion
rate; HGP, hepatic glucose production; Rd, rate
of glucose disposal. Data are expressed as
mean ± SEM; n = 4 for each genotype; *p < 0.05;
**p < 0.01 by Student’s t test.
(B) Glucose infusion rates during the euglycemic-
hyperinsulinemic clamp. 2- to 3-month-old male
control (Akt2(lox/lox)) and liver-specific Akt2 KO
(Akt2(lox/lox); AFP > CRE) mice were subjected to a
euglycemic clamp with infusion of insulin at 2.5
mU/kg/min. See also Figure S1.
(C) G6pc and Pck1 mRNA levels in the liver at the
termination of the clamp.
(D) Hepatic glycogen content after the termination
of the clamp. Data are expressed as mean ± SEM;
n = 5–7 for each condition; *p < 0.05; **p < 0.01 by
two-way ANOVA followed by the Bonferroni post
hoc test.
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Akt2 Regulates Hepatic Glycogen Contentglucose disposal (Rd) was also significantly reduced, indicating
that peripheral insulin resistance developed upon deletion of
Akt2 exclusively in liver (Leavens et al., 2009) (Figure 1A, left).
Next, Akt2(lox/lox); AFP > CRE mice and their controls were sub-
jected to a euglycemic clamp during infusion of PBS or insulin
at 2.5 mU/kg/min. Blood glucose levels were similar between
experimental groups when the clamp reached the steady state
(Figure S1). No glucose was given to mice infused with PBS
alone. Consistent with the data presented in Figure 1A, the GIR
was significantly lower in Akt2(lox/lox); AFP > CRE mice than
control mice during infusion (Figure 1B). At the end of the 3 hr100 Cell Metabolism 18, 99–105, July 2, 2013 ª2013 Elsevier Inc.clamp, expression of G6pc was lower
in the insulin-infused, compared to the
PBS-infused, mice, but there were no
differences between mice with or without
Akt2 in the liver (Figure 1C, left). Insulin
did not change the expression of Pck1
in liver from either the control or KO group
(Figure 1C, right). These results show
that the inability of insulin to completely
suppress HGP following deletion of
hepatic Akt2 cannot be explained by
changes in the expression of G6pc or
Pck1.
Glycogen Metabolism Is Disrupted
in Mice with Hepatic Deletion of
Akt2
Given the discordance between G6pc
and Pck1 gene expression and glucose
output in vivo in the Akt2(lox/lox); AFP >
CRE mice, we determined the fluxes
that contributed to glucose production
in Akt2 null and control livers using the
ex vivo isolated, perfused liver and iso-
topomer analysis (Burgess et al., 2004).Glucose production in livers rapidly isolated from control mice
was inhibited by insulin in control livers, while livers from Akt2
null mice did not respond to the hormone, reproducing the
euglycemic-hyperinsulinemic clamp (Figure 2A, left). As shown
in Figure 2A, brief exposure to insulin suppressed glycogen
breakdown in Akt2+/+ livers but had no effect on gluconeogen-
esis. In livers deficient for Akt2, insulin failed to suppress
glycogenolysis, and again there was no effect on gluconeo-
genesis (Figure 2A). If blunted glycogen synthesis contributed
to the altered glycogenmetabolism inAkt2KO livers, therewould
most likely be a corresponding reduction in glucose uptake and
Figure 2. Postprandial Hepatic Glycogen
Accumulation Is Blunted in the Akt2(lox/lox);
AFP > CRE Mice
(A) Livers from control and Akt2 KO mice were
perfused ex vivo, and glucose production, glyco-
genolysis, and gluconeogenesis wasmeasured by
isotopomer analysis of incorporated deuterium.
Data are expressed as mean ± SEM; n = 4–6 for
each condition; *p < 0.05; **p < 0.01 by two-way
ANOVA followed by the Bonferroni post hoc test.
(B–D) Male control (Akt2(lox/lox)) and liver-specific
Akt2 KO (Akt2(lox/lox); AFP > CRE) mice (2 months
old) were fasted overnight, refed, and, at 1 and
4 hr, assayed for (B) blood glucose and serum
insulin, (C) gene expression, and (D) hepatic
glycogen (left, 1 hr refed; right, 4 hr refed). Data are
expressed as mean ± SEM, n = 5–7; *p < 0.05;
**p < 0.01 by two-way ANOVA followed by the
Bonferroni post hoc test. See also Figures S2D
and S2E.
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Akt2 Regulates Hepatic Glycogen Contentphosphorylation. We took advantage of the release of radioac-
tivity from [2-3H]glucose-6-phosphate in the near-equilibrium
glucose-6-phosphate isomerase reaction to directly measure
glucokinase (GCK) flux (Christ et al., 1986; Massa et al., 2011).
Because of the relative unresponsiveness to insulin of primary
mouse hepatocytes, we isolated rat liver cells in which insulin
stimulated GCK flux about 50% (Figure S2A). The increased
flux was abrogated by two small molecule inhibitors of Akt,
Akt1/2-i andMK2066, that also blocked insulin-dependent phos-
phorylation of Akt, GSK3a and GSK3b, and ribosomal protein S6
(Somaiah and Simon, 2011) (Figures S2A–S2C). These data
further suggest that insulin regulates glucose flux from the extra-Cell Metabolism 18, 99cellular space into glycogen through a
pathway dependent on Akt.
To assess whether the defects in
glycogen synthesis and suppression of
glycogenolysis ex vivo in Akt2-deficient
liver are relevant to in vivo regulation
of glucose metabolism, we measured
hepatic glycogen at the end of the
euglycemic clamp. As shown in Fig-
ure 1D, the liver glycogen content from
control mice infused with insulin was
about 2.5-fold higher than that from
mice infused with PBS alone. However,
in mice without Akt2 in liver, hepatic
glycogen was the same in insulin- and
PBS-treated mice (Figure 1D). Next, we
fasted Akt2(lox/lox); AFP > CRE and control
mice overnight followed by refeeding.
Blood glucose and serum insulin levels
were indistinguishable between control
and Akt2(lox/lox); AFP > CRE mice before
and 1 and 4 hr after feeding, at which
times both were significantly elevated in
mice of both genotypes (Figure 2B). In
livers harvested 4 hr after feeding, G6pc
and Pck1 messenger RNA (mRNA) wasreduced compared to fasting levels, but this was unaffected
by deletion of Akt2 in the liver, and PEPCK protein levels were
unaltered under all the conditions tested (Figures 2C and S2E).
Although hepatic glycogen content was elevated at 1 or 4 hr
after refeeding in both Akt2(lox/lox); AFP > CRE and control
mice, there was a significant reduction of glycogen accumula-
tion in the liver of AFP > CRE mice (Figure 2D). The persistent
increase in glycogen in liver from Akt2(lox/lox); AFP > CRE mice
after feeding was most likely a result of augmented postprandial
glucose. Thus, these findings are largely in agreement with the
clamp results and suggest defective hepatic glycogen meta-
bolism in livers lacking Akt2.–105, July 2, 2013 ª2013 Elsevier Inc. 101
Figure 3. GSK3 Phosphorylation Is Not
Required for Insulin-Dependent Accumula-
tion of Glycogen in Liver
(A and B) Immunoblot for phosphorylated Akt and
GSK3a and GSK3b in livers from fasting mice at
1 hr (A) or 4 hr (B) after refeeding (upper panels).
Quantification of Akt and GSK3 phosphorylation is
shown in lower panels.
(C) Hepatic glycogen content at the termination
of the clamp. Male control or GSK3aS21A/S21A;
bS9A/S9A mice (3 months old) were infused with
PBS or insulin at 10 mU/kg/min while glucose was
clamped as in Figure 2. Data are expressed as
mean ± SEM; n = 6–7 for each condition; *p < 0.05
by two-way ANOVA followed by the Bonferroni
post hoc test. See also Figure S3.
(D–F) GSK3aS21A/S21A;bS9A/S9A mice and their
controls were fasted overnight followed by 1 hr
refed. (D) Blood glucose levels, (E) serum insulin
levels, and (F) hepatic glycogen content were
assayed at fasting and refeeding. n = 5 for
each condition. Data are expressed as mean ±
SEM; **p < 0.01 by two-way ANOVA followed
by the Bonferroni post hoc test. See also
Figures S2A–S2C.
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to refeeding was blunted in Akt2(lox/lox); AFP > CRE mice (Fig-
ure S2D). However, GCK protein did not change after refeeding
in either the Akt2(lox/lox); AFP > CRE or control mice (Figure S2E).
Thus, changes in the amount of total hepatic GCK cannot
account for the defect in glycogen synthesis in Akt2(lox/lox);
AFP > CRE mice.
The Hepatic GSK3-GS Signaling Cascade Remains
Responsive to Insulin and Refeeding in Akt2(lox/lox);
AFP > CRE Mice
Akt phosphorylates and inhibits GSK3a and GSK3b, which in
turn (by phosphorylation) inhibits glycogen synthase (Cross102 Cell Metabolism 18, 99–105, July 2, 2013 ª2013 Elsevier Inc.et al., 1995; McManus et al., 2005). At
1 hr after refeeding, livers of control
mice displayed a slight increase in phos-
phorylation of S473 in Akt and S21 and
S9 in GSK3a and GSK3b, which was
more obvious 4 hr after refeeding (Fig-
ures 3A and 3B). In Akt2(lox/lox); AFP >
CRE mice, phosphorylation of Akt was
substantially decreased, while that of
GSK3a and GSK3b was only slightly
reduced (Figures 3A and 3B). The lack
of defect in GSK3a and GSK3b phos-
phorylation in Akt2(lox/lox); AFP > CRE
mice suggested that this pathway was
not responsible for the altered glycogen
accumulation. To test thismore definitely,
mice expressing GSK3a and GSK3b
mutants that cannot be phosphorylated
and inhibited by Akt were subjected
to euglycemic-hyperinsulinemic clamp,
and the insulin-dependent accumulationof hepatic glycogen was assessed. GSK3aS21A/S21A;bS9A/S9A
knockin mice, in which the major Akt sites (S21 and S9 of
GSK3a and GSK3b, respectively) were replaced by alanine in
the endogenous loci, have normal blood glucose and hepatic
glycogen during the fed state, but their response to insulin
has not been investigated (McManus et al., 2005). As shown
in Figures S3A and S3B, during a euglycemic-hyperinsulinemic
clamp, the GIR was indistinguishable between control
and GSK3aS21A/S21A;bS9A/S9A mice. Similarly, insulin infusion
increased hepatic glycogen content in both GSK3aS21A/S21A;
bS9A/S9A and control mice to the same extent (Figure 3C). Con-
sistent with these data, when GSK3aS21A/S21A;bS9A/S9A mice
were fasted overnight and refed for 1 hr, their blood glucose,
Figure 4. Glycogen Synthase Activity Is
Blunted after Refeeding in the Akt2(lox/lox);
AFP > CRE Mice
(A) Immunoblot for phosphorylated glycogen
synthase (GS) and glycogen phosphorylase (GP) in
livers from fasting mice and 1 hr after refeeding.
(B) Hepatic GS activity after 1 hr refeeding. Data
are expressed as mean ± SEM; **p < 0.01 by two-
way ANOVA followed by the Bonferroni post hoc
test. See also Figure S4.
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Akt2 Regulates Hepatic Glycogen Contentserum insulin levels, and hepatic glycogen content were indistin-
guishable from that of controls (Figures 3D–3F). These data
contrast with that from mice lacking hepatic Akt2 (Figures 1
and 2), which had a reduced accumulation of glycogen in liver,
demonstrating that the regulation of hepatic glycogen requires
Akt2, but not phosphorylation of GSK3a and GSK3b.
To address the role of GSK3 in an in vitro experimental system,
GSK3a andGSK3bwere blocked pharmacologically by LiCl, and
GCK flux was assessed. Though LiCl did increase basal flux, it
did not abrogate the response to insulin (Figures S2A–S2C).
The efficacy of LiCl in inhibiting GSK3a and GSK3b is indicated
by the increased ribosomal protein S6 phosphorylation in the
presence of LiCl (Inoki et al., 2006) (Figures S2B and S2C). These
data further support the idea that insulin regulates glycogen
deposition through a pathway dependent on Akt, but not GSK3
phosphorylation.
At 1 hr after refeeding, phosphorylation of GS at S641 was
reduced to the same extent in livers from control and Akt2(lox/
lox); AFP > CRE mice. We were unable to detect any consistent
change in phosphorylation of GP at S15 (Figure 4A). At the
same time, the postprandial increase in glycogen synthase activ-
ity was blunted in the livers of Akt2(lox/lox); AFP > CRE mice to
about the same extent as reduction in glycogen levels (Figures
2D and 4B). By 4 hr, the decrease in GS phosphorylation was
no longer evident in livers from either control of liver-specific
Akt2 KO mice (Figure S4A). However, at this time there was still
a substantial increase in GS activity, which was unaltered in
livers lacking Akt2 (Figure S4B). In both control and liver-specific
Akt2 KO mice, we were unable to detect a consistent change in
GS or GP phosphorylation or activity in response to two concen-
trations of insulin when blood glucose was held at physiological
levels, even though there was the expected increase in Akt phos-
phorylation (Figures S4C–S4E).
DISCUSSION
One of the criteria for the diagnosis of type 2 diabetes mellitus is
the extent of rise in blood sugar following a glucose tolerance
test. The glycemic excursion is determined both by the insulin-
dependent clearance of glucose as well as the suppression of
hepatic glucose output. Understanding the normal signaling
pathways that govern the latter process is critical to defining
its dysfunction in insulin-resistant states. The mild impairment
in hepatic insulin action present in the Akt2(lox/lox); AFP > CRECell Metabolism 18, 99mice that is best revealed by the euglyce-
mic-hyperinsulinemic clamp is consistent
with the perceived importance of phos-phoinositide-3-kinase (PI3K)-Akt signaling cascade for many, if
not all, of the metabolic actions of insulin. Since suppression of
key gluconeogenic genes remains intact during clamp or
following a meal, these data point to critical regulatory steps
other than gene expression, which are likely associated with
defects in the suppression of hepatic glucose production. The
immediate response of the liver to insulin or feeding is to redirect
glucose-6-phosphate derived from gluconeogenesis and blood
glucose to glycogen, thus effectively suppressing glycogenol-
ysis (Edgerton et al., 2001; Newgard et al., 1983; Shulman
et al., 1985). In humans, who have residual hepatic glycogen
after an overnight fast, feeding both stimulates glycogen syn-
thesis and suppresses glycogenolysis (Rothman et al., 1991;
Taylor et al., 1996). Given the substantive level of recycling of
glycogen, it is likely that a coordinated regulation of both syn-
thesis and degradation is involved in the postprandial regu-
lation of hepatic glycogen metabolism even when the normal
coupling between GS and GP is disrupted (David et al., 1990;
Petersen et al., 1998). Since insulin’s major role is to redirect
glucose to glycogen, it stands to reason that the primary defect
in Akt2(lox/lox); AFP > CREmice would be in this process, which is
also dysfunctional in human insulin-resistant states (Krssak
et al., 2004).
A well-defined pathway has been established by which insulin
is thought to promote deposition of glycogen (Cohen, 1999).
Activated Akt phosphorylates and inhibits GSK3, which is a
negative regulator of GS through phosphorylation. Recently,
the importance of this signaling cascade to the control of skeletal
muscle glycogen storage has been questioned (Bouskila et al.,
2008; McManus et al., 2005). Bouskila et al., (2010) concluded
that allosteric activation of GS by glucose-6-phosphate, rather
than the canonical GSK3a and GSK3b pathway, is the predom-
inant mechanism for control of glycogen synthesis in skeletal
muscle. Unlike skeletal muscle, glucose transport in liver is not
insulin responsive and thus cannot drive an increase in intracel-
lular glucose-6-phosphate in response to hormone when blood
glucose is unchanged; this eliminates the possibility that liver
regulates glycogen synthesis by a mechanism strictly analogous
to muscle. In this study, we observed a lack of correlation
between GS activity and phosphorylation of GS S641, a target
of GSK3a and GSK3b known as site 3a (Figures 4 and S4)
(Roach et al., 2012). These data suggest that posttranslational
modification of GS at another residue might be modulated
by the insulin/Akt pathway and important for enzyme activity.–105, July 2, 2013 ª2013 Elsevier Inc. 103
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only by GSK3a and GSK3b, but also by kinases such as cAMP-
dependent protein kinase and by acetylation of lysine residues
(Roach et al., 2012). Nonetheless, here we show that in liver,
like muscle, Akt phosphorylation of GSK3a and GSK3b is
unlikely to be the primary means by which insulin stimulates
glycogen deposition. Unlike Akt2(lox/lox); AFP > CREmice, which
were defective in insulin- and refeeding-dependent glycogen
accumulation, insulin- and food-induced glycogen synthesis
was completely normal in GSK3aS21A/S21A;bS9A/S9A mice
(Figures 3C and S3). Taken with the biochemical data, these
results provide compelling evidence that insulin can suppress
glycogenolysis and promote glycogen accumulation in an
Akt-dependent manner that does not depend on phosphory-
lation of GSK3a and GSK3b.
In order to gather further information regarding themechanism
by which insulin increases glycogen deposition in liver, we
measured glucose flux through GCK directly in hepatocytes
ex vivo (Figures S2A). Isolated mouse liver cells are minimally in-
sulin responsive, so we relied on primary rat hepatocytes, which
precluded the use of the genetically modifiedmice; therefore, we
relied on pharmacologic inhibition. Two different Akt inhibitors
blocked the insulin-dependent increase in GCK flux, supporting
a model in which extracellular glucose provides substrate for at
least some of the glycogen synthesized in response to insulin.
This experiment cannot distinguish whether the increased flux
is caused by a change in activity intrinsic to GCK or is
secondary to activation of GS. However, since glucose-6-phos-
phate levels are reduced following a euglycemic-hyperinsuline-
mic clamp, it is more likely that insulin stimulates flux into
glycogen at a step downstream of GCK (Guignot and Mithieux,
1999; Halimi et al., 1987). The inability of the GSK3 inhibitor
LiCl to block the insulin effect on GCK flux, combined with the
in vivo data using the GSK3aS21A/S21A;bS9A/S9A mice, provide
compelling evidence that the enhanced conversion of glucose
to glycogen is not mediated by phosphorylation of GSK3a
and GSK3b.
In summary, we have confirmed the major role of insulin in the
acute suppression of hepatic glucose output. Under euglyce-
mic-hyperinsulinemic clamp and more physiological postpran-
dial conditions, insulin inhibits hepatic glucose production by
suppressing glycogenolysis and redirecting glucose-6-phos-
phate to glycogen, which is dependent on Akt2, but not GSK3
phosphorylation. Complete characterization of this unexpected
pathway may provide insight into the insulin resistance of
T2DM and suggest a site for therapeutic intervention.EXPERIMENTAL PROCEDURES
Animals
The Akt2/, Akt2(lox/lox); AFP > CRE, and GSK3aS21A/S21A;bS9A/S9A mice have
been described previously (Cho et al., 2001; Leavens et al., 2009; McManus
et al., 2005). The Akt2/ and GSK3aS21A/S21A;bS9A/S9A mice were back-
crossed more than ten generations onto C57Bl/6J purchased from Jackson
Laboratory. The Akt2(lox/lox); AFP > CRE and Akt2(lox/lox) mice (controls) were
on a C57Bl/6J and FVB mixed background. Mice were maintained on a
standard chow diet (laboratory rodent diet 5001, LabDiet) and 12 hr light/
dark cycle (7 am to 7 pm) in a barrier facility and treated with approval from
the University of Pennsylvania IACUC in accordance with NIH guidelines.
For the fasting-refeeding experiment, mice were fasted overnight and then104 Cell Metabolism 18, 99–105, July 2, 2013 ª2013 Elsevier Inc.refed with normal diet starting at 10 am for 1 or 4 hr. Mice were sacrificed by
spinal dislocation, and livers were quickly removed and freeze clamped in
liquid nitrogen. All animal experiments were approved by the University of
Pennsylvania’s Institutional Animal Care and Use Committee.
Liver Perfusion and Isotopomer Analysis
Germline Akt2/mice and controls were shipped blinded from the University
of Pennsylvania to the University of Texas Southwestern, where they were
maintained on a standard chow diet and light/dark cycle for 3 weeks prior to
experiments. The procedure and rational for liver perfusion were described
previously (Burgess et al., 2004). Briefly, ad libitum fed mice were anesthe-
tized, and the portal vein was cannulated. Nonrecirculating buffer was
perfused at 8 ml/min starting with dissection of the hepatic vein and artery.
Perfusion media was a standard oxygenated Krebs-Henseleit buffer contain-
ing a 0.4 mM algal mixture of free fatty acids bound to 3% albumin,
0.25 mM glycerol, 1.5 mM lactate, 0.15 mM pyruvate, 0.1 mM [U-13C]propio-
nate, and 2% 2H2O. Livers were acclimated for 15 min before samples were
collected for glucose output and 2H enrichment over the next 30 min. Insulin
was then infused into the perfusion cannula at a rate equivalent to 10 ng/ml,
and samples were collected for an additional 30 min. Glucose deuterium
enrichments were measured by 2H-NMR and used to determine the fractional
rates of gluconeogenesis and glycogenolysis as previously described
(Burgess et al., 2004).
Euglycemic Clamp
The euglycemic-hyperinsulinemic clamp for Figure 1A was performed by the
Mouse Phenotyping, Physiology, and Metabolism Core at the University of
Pennsylvania. Mice were fasted for 6 hr and given a bolus of 16 mU/kg insulin
at the beginning of the clamp. GIR and Rd were measured using a priming
10 mCi [3-3H]glucose bolus followed by 0.1 mCi/min perfusion throughout
the clamps. The rate of insulin infusion was 2.5 mU/kg/min, and the glucose
infusion rate was adjusted to keep euglycemic levels between 120 and
140 mg/dl. The insulin values range from 0.843 to 1.203 ng/ml before clamp
and from 4.049 to 8.412ng/ml after clamp. The clamp period lasted for 2 hr
total, and the data presented in Figure 1 were calculated from the steady state
of the clamp (the last 40 min of the 2 hr clamp).
The euglycemic clamp performed in Figures S1 and S3 was as previously
described (Ayala et al., 2006). Mice were fasted for 5 hr prior to the clamp.
No bolus of insulin was given, and insulin perfusion rate was constant at either
2.5 mU/kg/min or 10 mU/kg/min as indicated in the figure legend. Glucose
infusion rate was adjusted to match the blood glucose levels in the control
mice and maintained in general between 100 and 140 mg/dl. Only PBS was
infused in the control groups. Blood drops were taken through tail bleeding,
and blood glucose levels were measured every 10 min during the clamp. At
the end of the 3 hr clamp, mice were sacrificed by spinal dislocation, and livers
were quickly removed, freeze clamped in liquid nitrogen, and stored at 80C
for future uses.
Statistics
All data are presented as mean ± SEM. As noted in figure legends, data were
analyzed by using unpaired Student’s t test with two-tailed analysis or two-
way ANOVA followed by Bonferroni post hoc test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2013.06.001.
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